Fiche centre
Research Site
Lanzhou — China
Essais liés6clinical trials
VilleLanzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07691970
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Dapagliflozin | Maladie rénale chronique | Phase 4 | NCT06610526 | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Myopathies | Phase 3 | NCT07691970 | ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | RECRUITING |
| Baxdrostat/dapagliflozin | Hypertension | Phase 3 | NCT06742723 | BaxDuo-Pacific — A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | RECRUITING |
| MG Cohort — A Study in Patients With Myasthenia Gravis in China | Myasthénie | À vérifier | NCT06700616 | MG Cohort — A Study in Patients With Myasthenia Gravis in China | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT07751848 | LOTUS — A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus | RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |